Pharmaceutical

FDA approves YolTech’s YOLT-101 for familial hypercholesterolemia

YolTech has received FDA approval for its investigational new drug (IND) application for YOLT-101 to treat HeFH.

Jun 11, 2025 - 06:00
FDA approves YolTech’s YOLT-101 for familial hypercholesterolemia
YolTech has received FDA approval for its investigational new drug (IND) application for YOLT-101 to treat HeFH.
Read the original article

Tags:

Previous Article

EC approves Alnylam’s vutrisiran for ATTR-CM treatment

Next Article

Podcast: AI and Supervised Machine Learning in Clinical Trials – Part 2

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Under-the-skin injection of Eisai’s Leqembi is as effective as IV infusion, new Alzheimer’s data show

STAT+: Under-the-skin injection of Eisai’s Leqembi is a...

Oct 26, 2023

STAT+: Six months after launch, Bert Vogelstein’s latest blood testing startup gets acquired for $450 million

STAT+: Six months after launch, Bert Vogelstein’s lates...

Apr 27, 2023

Exodus of life scientists from academia reaches historic levels, new data show

Exodus of life scientists from academia reaches histori...

Sep 28, 2023